Status:
NOT_YET_RECRUITING
Additional Effect of Steroid on Hyaluronic Acid in Subdeltoid Bursitis
Lead Sponsor:
Shin Kong Wu Ho-Su Memorial Hospital
Conditions:
Subdeltoid Bursitis of the Shoulder
Eligibility:
All Genders
20+ years
Phase:
PHASE4
Brief Summary
The study employs a double-blind, randomized clinical trial design with 60 patients diagnosed with subdeltoid bursitis. Participants are divided into two groups: the experimental group receives combin...
Detailed Description
Evaluation indicators include pain (measured by Visual Analog Scale for rest, activity, and sleep, and pain threshold via pressure algometer), function (assessed by Disabilities of the Arm, Shoulder, ...
Eligibility Criteria
Inclusion
- \- Unilateral shoulder pain within the past 3 months
- Pain during joint movements such as abduction or internal rotation
- At least one positive result from the following tests: Painful arc, Neer test, or Hawkins test
- No shoulder injections received in the past 3 months
- Willingness to receive injection treatment and undergo follow-up assessments at the following time points:
- Immediate (1 week after injection)
- Short-term (1 month after injection)
- Mid-term (3 months after injection)
- Avoid use of anti-inflammatory painkillers during the study period as much as possible; if intolerable pain occurs, acetaminophen (provided by the researcher) will be used to relieve symptoms
Exclusion
- Presence of infectious disease, inflammation, rheumatoid arthritis, or fracture
- History of malignancy
- Previous shoulder surgery
- Sensory deficits
- Tendon rupture of the rotator cuff or biceps tendon
- Neurological disorders causing hand weakness or affecting shoulder mobility (e.g., stroke, Parkinson's disease, brachial plexus injury, peripheral neuropathy)
- Cognitive impairment preventing completion of questionnaires
- Cervical radiculopathy
- Diagnosed frozen shoulder (adhesive capsulitis)
- Psychiatric disorders
- Breastfeeding or pregnant women
- Received shoulder injection within the past 3 months, including corticosteroids, hyaluronic acid, Platelet-rich plasma, or any prolotherapy solution
Key Trial Info
Start Date :
April 25 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06935877
Start Date
April 25 2025
End Date
June 30 2026
Last Update
April 24 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.